Association between BRCA1 and BRCA2 Mutations and Survival in Women with Invasive Epithelial Ovarian Cancer

Autor: Fridley, BL, Goode, EL, Høgdall, E, Jensen, A, Cass, I, Kjær, SK, Johnatty, SE, Nicoletto, MO, D'Andrea, E, Montagna, M, Blanco, I, Lázaro, C, Ma, ESK, Daly, MB, Godwin, AK, Eeles, R, Evans, DG, Frost, D, Peock, S, Hartge, P, Gail, MH, Neuhausen, S, García, MJ, Benítez, J, Sinilnikova, O, Easton, DF, Healey, S, McGuffog, L, Barrowdale, D, Despierre, E, Lambrechts, D, Karlan, BY, Ramus, SJ, Sadetzki, S, Goh, C, ChenevixTrench, G, Bolton, KL, Li, AJ, Walsh, C, Gross, J, Steele, L, Beattie, MS, Chan, S, Nussbaum, RL, Moysich, KB, Leuchter, R, Borg, Å, Olsson, H, Kristoffersson, U, Sieh, W, McGuire, V, Whittemore, AS, Tyrer, J, Song, H, Michie, CO, Gourley, C, Gore, ME, Senter, L, Toland, AE, Glendon, G, HirshYechezkel, G, Lubin, F, Chetrit, A, Mai, PL, Greene, MH, Loud, JT, Levine, DA, Gordon, O, GarciaClosas, M, Gayther, SA, Chanock, SJ, Antoniou, AC, Pharoah, PDP, Andrulis, IL, Kwong, A

Context: Approximately 10% of women with invasive epithelial ovarian cancer (EOC) carry deleterious germline mutations in BRCA1 or BRCA2. A recent article suggested that BRCA2-related EOC was associated with an improved prognosis, but the effect of B

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od_______961::26300e4c4ad8b29c56279357f406856d
http://hdl.handle.net/10722/182264

Real world study of sacituzumab govitecan in metastatic triple-negative breast cancer in the United Kingdom.

Autor: Hanna D; St. Bartholomew's hospital, Barts Health NHS trust, London, UK. daire.hanna@nhs.net.; Barts Cancer Institute, Queen Mary University, London, UK. daire.hanna@nhs.net., Merrick S; UCLH NHS foundation trust, London, UK., Ghose A; St. Bartholomew's hospital, Barts Health NHS trust, London, UK., Devlin MJ; St. Bartholomew's hospital, Barts Health NHS trust, London, UK., Yang DD; The Royal Marsden NHS foundation trust London and Sutton, London, UK., Phillips E; The Royal Marsden NHS foundation trust London and Sutton, London, UK., Okines A; The Royal Marsden NHS foundation trust London and Sutton, London, UK., Chopra N; The Royal Free, London NHS foundation trust, London, UK., Papadimatraki E; UCLH NHS foundation trust, London, UK., Ross K; Beatson West of Scotland Cancer Centre, Glasgow, UK., Macpherson I; Beatson West of Scotland Cancer Centre, Glasgow, UK., Boh ZY; Edinburgh Cancer Centre and University of Edinburgh, Edinburgh, UK., Michie CO; Edinburgh Cancer Centre and University of Edinburgh, Edinburgh, UK., Swampillai A; Guy's and St Thomas' NHS foundation trust, London, UK., Gupta S; Guy's and St Thomas' NHS foundation trust, London, UK., Robinson T; Bristol Haematology and Oncology Centre- NHS foundation trust, Bristol, UK., Germain L; Leeds Cancer Centre, Leeds, UK., Twelves C; Leeds Cancer Centre, Leeds, UK., Atkinson C; Taunton and Somerset NHS foundation trust, Taunton, UK., Konstantis A; UCLH NHS foundation trust, London, UK.; Princess Alexandra Hospital NHS trust, London, UK., Riddle P; Chelsea and Westminster, London, UK., Cresti N; Northern Centre for Cancer Care, Newcastle upon Tyne Hospital NHS Foundation Trust, Newcastle upon Tyne, UK., Naik JD; Harrogate and District NHS foundation trust, Harrogate, UK., Borley A; Velindre Cancer Centre, Cardiff, UK., Guppy A; Mount Vernon Cancer Centre, London, UK., Schmid P; St. Bartholomew's hospital, Barts Health NHS trust, London, UK., Phillips M; St. Bartholomew's hospital, Barts Health NHS trust, London, UK.

Publikováno v: British journal of cancer [Br J Cancer] 2024 Jun; Vol. 130 (12), pp. 1916-1920. Date of Electronic Publication: 2024 Apr 24.

Multiomic Characterization of High-Grade Serous Ovarian Carcinoma Enables High-Resolution Patient Stratification.

Autor: Hollis RL; Nicola Murray Centre for Ovarian Cancer Research, Cancer Research UK Scotland Centre, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK., Meynert AM; MRC Human Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK., Michie CO; Edinburgh Cancer Centre, Western General Hospital, NHS Lothian, Edinburgh, UK., Rye T; Nicola Murray Centre for Ovarian Cancer Research, Cancer Research UK Scotland Centre, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK., Churchman M; Nicola Murray Centre for Ovarian Cancer Research, Cancer Research UK Scotland Centre, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK., Hallas-Potts A; Nicola Murray Centre for Ovarian Cancer Research, Cancer Research UK Scotland Centre, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK., Croy I; Nicola Murray Centre for Ovarian Cancer Research, Cancer Research UK Scotland Centre, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK., McCluggage WG; Department of Pathology, Belfast Health and Social Care Trust, Belfast, UK., Williams ARW; Division of Pathology, The Royal Infirmary of Edinburgh, Edinburgh, UK., Bartos C; Nicola Murray Centre for Ovarian Cancer Research, Cancer Research UK Scotland Centre, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK., Iida Y; Nicola Murray Centre for Ovarian Cancer Research, Cancer Research UK Scotland Centre, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK.; The Jikei University School of Medicine, Tokyo, Japan., Okamoto A; The Jikei University School of Medicine, Tokyo, Japan., Dougherty B; Translational Medicine, Oncology R&D, AstraZeneca, Waltham, Massachusetts., Barrett JC; Translational Medicine, Oncology R&D, AstraZeneca, Waltham, Massachusetts., March R; Precision Medicine and Biosamples, Oncology R&D, AstraZeneca, Cambridge, UK., Matakidou A; Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Roxburgh P; Institute of Cancer Sciences, Wolfson Wohl Cancer Research Centre, University of Glasgow, Belfast, UK.; Beatson West of Scotland Cancer Centre, Glasgow, UK., Semple CA; MRC Human Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK., Harkin DP; Almac Diagnostics, Craigavon, UK.; Centre for Cancer Research and Cell Biology, Queen's University Belfast, Belfast, UK., Kennedy R; Almac Diagnostics, Craigavon, UK.; Centre for Cancer Research and Cell Biology, Queen's University Belfast, Belfast, UK., Herrington CS; Nicola Murray Centre for Ovarian Cancer Research, Cancer Research UK Scotland Centre, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK., Gourley C; Nicola Murray Centre for Ovarian Cancer Research, Cancer Research UK Scotland Centre, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK.

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2022 Aug 15; Vol. 28 (16), pp. 3546-3556.

Expression of glycolytic enzymes in ovarian cancers and evaluation of the glycolytic pathway as a strategy for ovarian cancer treatment.

Autor: Xintaropoulou C; Cancer Research UK Edinburgh Centre and Division of Pathology Laboratory, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, EH4 2XU, UK., Ward C; Cancer Research UK Edinburgh Centre and Division of Pathology Laboratory, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, EH4 2XU, UK.; The Royal (Dick) School of Veterinary Studies and Roslin Institute, Easter Bush, Roslin, Midlothian, EH25 9RG, UK., Wise A; IOmet Pharma (a wholly owned subsidiary of Merck & Co., Inc., Kenilworth, NJ USA, known as MSD outside the United States and Canada) Nine Edinburgh Bioquarter, Little France Road, Edinburgh, EH16 4UX, UK., Queckborner S; Cancer Research UK Edinburgh Centre and Division of Pathology Laboratory, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, EH4 2XU, UK., Turnbull A; Cancer Research UK Edinburgh Centre and Division of Pathology Laboratory, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, EH4 2XU, UK., Michie CO; Cancer Research UK Edinburgh Centre, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, EH4 2XU, UK., Williams ARW; Division of Pathology, University of Edinburgh Medical School, 51 Little France Crescent, Edinburgh, EH16 4SA, UK., Rye T; Cancer Research UK Edinburgh Centre, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, EH4 2XU, UK., Gourley C; Cancer Research UK Edinburgh Centre, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, EH4 2XU, UK., Langdon SP; Cancer Research UK Edinburgh Centre and Division of Pathology Laboratory, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, EH4 2XU, UK. simon.langdon@ed.ac.uk.

Publikováno v: BMC cancer [BMC Cancer] 2018 Jun 05; Vol. 18 (1), pp. 636. Date of Electronic Publication: 2018 Jun 05.

Does shear wave ultrasound independently predict axillary lymph node metastasis in women with invasive breast cancer?

Autor: Evans A; Dundee Cancer Centre, Ninewells Hospital & Medical School, Mailbox 4, Dundee, DD1 9SY, UK, a.z.evans@dundee.ac.uk., Rauchhaus P, Whelehan P, Thomson K, Purdie CA, Jordan LB, Michie CO, Thompson A, Vinnicombe S

Publikováno v: Breast cancer research and treatment [Breast Cancer Res Treat] 2014 Jan; Vol. 143 (1), pp. 153-7. Date of Electronic Publication: 2013 Dec 04.